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Alzheimer’s disease (AD) is a devastating neurodegenera-
tive disorder affecting roughly 30 million people worldwide. 
Although some cases of AD (<1%) are caused by autoso-
mal-dominant inherited mutations that typically lead to clin-
ical disease onset before the age of 60, the majority of AD is 
late-onset AD (LOAD) where age, genetics, environment, and 
other diseases likely play a role (Holtzman et al., 2011; Musiek 
and Holtzman, 2015). AD is characterized by a cascade of 
pathological events, including the formation of amyloid 
plaques (made up of aggregated forms of Aβ), neurofibril-
lary tangles (composed of aggregated, hyperphosphorylated 
tau), synapse loss, brain hypometabolism, neuroimflammation, 
and brain atrophy that is accompanied by severe and pro-
gressive cognitive impairment. Amyloid plaques, consisting of 
aggregated forms of Aβ in the extracellular space, are gen-
erated in a concentration-dependent manner. The buildup 
of hyperphosphorylated and aggregated tau protein leads to 
the development of intracellular neurofibrillary tangles. Ac-
cumulation of Aβ occurs ∼15 yr before patients experience 
cognitive decline, whereas tau begins to accumulate in the 
neocortex later but before the onset of dementia, adding to 
the complexity of this disease. Many risk factors for LOAD, 
both genetic and nongenetic, have been identified. Apart from 
aging, the strongest known risk factor for LOAD is genetic 
variation in the apolipoprotein E (APOE) gene. The APOE4 
allele increases AD risk by 12-fold (two copies) or 3.7-fold 
(one copy) in part by influencing Aβ accumulation. However, 
APOE4 is only present in ∼50–60% of individuals with AD, 
suggesting that other factors are involved in AD pathogenesis 
(Holtzman et al., 2011).
One such risk factor for LOAD, which has received 
considerable attention is type 2 diabetes (T2D), which in-
creases AD risk by at least twofold (Sims-Robinson et al., 
2010). Also a disease of aging, T2D is characterized by hy-
perglycemia, hyperinsulinemia, and insulin resistance (a lack 
of response in the insulin signaling [IS] pathway). Normally, 
insulin binds to the insulin receptor (IR) which phosphor-
ylates IR substrate (IRS) on a tyrosine residue, leading to 
activation of the canonical signaling cascade (Fig. 1). In pe-
ripheral tissues, such as muscle, fat, and liver, this signaling 
ultimately leads to the uptake and sequestration of glucose 
to satisfy cellular energy requirements and plays a key role 
in lipid metabolism (Dimitriadis et al., 2011). Contrary to 
the periphery, where glucose uptake is largely insulin depen-
dent, the brain uses nearly 20% of all glucose in the body in 
a process that is largely insulin independent. However, brain 
IS is robust and has pleotropic effects due to the widespread 
distribution of IRs throughout the brain and the complexity 
of IR signaling. For example, hippocampal activation of IR 
signaling can modulate memory (McNay et al., 2010) and 
IR signaling in the hypothalamus can affect feeding behavior 
and peripheral metabolism (Brief and Davis, 1984). Similar 
to AD, pathological changes in insulin occur years before pa-
tients receive a diagnosis of T2D, which typically occurs once 
pancreatic β cell dysfunction and insulin resistance produce 
chronic hyperglycemia (Dankner et al., 2009). Interestingly, 
T2D alone has been associated with cognitive decline (Allen 
et al., 2004), brain hypometabolism (Roberts et al., 2014), and 
regional brain atrophy (Last et al., 2007). The cognitive defi-
cits in T2D are proposed to be mediated by changes in brain 
IS (McNay and Recknagel, 2011), although there is little data 
from T2D patients measuring insulin/IS in the CNS to sup-
port this assertion (Liu et al., 2011).
Individuals with type 2 diabetes have an increased risk for developing Alzheimer’s disease (AD), although the causal relation-
ship remains poorly understood. Alterations in insulin signaling (IS) are reported in the AD brain. Moreover, oligomers/fibrils 
of amyloid-β (Aβ) can lead to neuronal insulin resistance and intranasal insulin is being explored as a potential therapy for 
AD. Conversely, elevated insulin levels (ins) are found in AD patients and high insulin has been reported to increase Aβ levels 
and tau phosphorylation, which could exacerbate AD pathology. Herein, we explore whether changes in ins and IS are a cause 
or consequence of AD.
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There are two broad ways in which T2D could influ-
ence the risk of AD: (1) T2D can lead to small vessel disease, 
which can cause or contribute to dementia, independent of 
or together with AD pathology, by disrupting proper function 
of the brain vasculature (Biessels and Reijmer, 2014), and (2) 
T2D can result in changes of brain function directly or in-
teract with key proteins or pathways involved in AD pathol-
ogy, such as Aβ or tau. This review will focus on mechanisms 
specific to AD pathology, but acknowledges the significant 
impact that vascular alterations may have on the brain in 
AD and other dementias.
Over the past 15 yr, many studies have reported changes 
in insulin levels (ins) or IS (ins/IS) in LOAD patients (Table 1), 
suggesting that individuals with AD experience hyperinsulin-
emia and brain insulin resistance. One interpretation is that 
the brain becomes insulin resistant as a consequence of AD 
pathology and hyperinsulinemia is compensatory, producing 
what has been termed type 3 diabetes (Steen et al., 2005). 
Insulin resistance in the AD brain may lead to cognitive im-
pairment, similar to that observed in T2D patients, therefore 
treating individuals with AD with intranasal insulin to im-
prove memory is currently under investigation in clinical 
trials (Reger et al., 2008; Craft et al., 2012; Wadman, 2012). 
Conversely, hyperinsulinemia and insulin resistance can mod-
ulate Aβ and tau in ways that can put the brain at risk to 
develop further AD pathology, so that changes in the ins/IS 
in AD patients may represent a contributor/cause of disease 
progression (Fig. 2). If so, increasing brain insulin could ex-
acerbate AD pathology and cognitive decline over time. This 
proposes a unique problem as it relates to AD; whereas insulin 
treatment may lead to modest cognitive improvement in AD 
patients, it could also worsen underlying pathology. In this 
review, we will analyze the changes in ins/IS that have been 
reported in AD and speculate if they are a cause or conse-
quence of disease based on experimental evidence and the 
timeline of AD progression. Critical evaluation of this liter-
ature as well as a determination of essential future experi-
ments is crucial, as rates of both T2D and AD are on the rise 
and insulin therapy is actively being pursued worldwide in 
older adults and patients.
INS ULIN-REL ATED CHA NGES IN AD
Brain insulin. Many groups have analyzed postmortem brain 
tissue from AD patients of varying severity and controls to 
look for alterations in Ins/IS through changes in mRNA, 
protein, or phosphorylation (Table 1). Insulin has been mea-
sured in relatively low levels in brain tissue of humans and ro-
dents (Banks et al., 1997; Frölich et al., 1998). Only one study 
reports insulin levels in the AD brain. They found that brain 
insulin was equally reduced in AD patients and age-matched 
controls, indicating that reductions in brain insulin are likely a 
result of age, not AD (Frölich et al., 1998).Two other groups 
report reductions in insulin mRNA in AD (Rivera et al., 
2005; Steen et al., 2005), yet questions remain as to whether 
insulin is synthesized in the brain to an appreciable level be-
cause there is evidence that a majority of brain insulin comes 
from the blood (Banks, 2004). Specifically, one study could 
not detect insulin mRNA in the cortex (Steen et al., 2005) 
but another did (Rivera et al., 2005), making this mRNA 
data difficult to interpret. Ultimately, a greater understand-
Figure 1. Canonical IR signaling cascade. Insulin binds to the insulin receptor (IR), a receptor tyrosine kinase, which autophosphorylates and activates a 
cascade of phosphorylation events. IRS1 is phosphorylated on a tyrosine residue to activate further signaling, which ultimately leads to the translocation of 
glucose transporter 4 (GLUT4) to the membrane and uptake of glucose for energy in peripheral tissues. Solid arrows represent activation upon insulin stim-
ulation. Blocked arrows represent inhibition. Glycogen synthase kinase 3 (GSK3) is serine phosphorylated and inhibited in response to insulin stimulation. 
Dashed arrows represent downstream effectors that have been found to phosphorylate IRS1 on a serine residue (p(Ser)-IRS1), which is thought to lead to 
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ing of insulin in the brain relative to the severity of AD and 
age-matched controls needs to be obtained in order to fully 
comprehend insulin’s function in healthy and diseased brains.
Brain IS. IRs are widely distributed throughout the brain, 
with relatively high concentrations in the olfactory bulb, hy-
pothalamus, and hippocampus (Fernandez and Torres-Alemán, 
2012). IRs are largely localized to neurons (Unger et al., 
1989), although IR mRNA is present in glia and endothelial 
cells (Zhang et al., 2014). Although alterations in IR levels 
(Frölich et al., 1998; Steen et al., 2005) and its phosphoryla-
tion (Steen et al., 2005) are reported in AD, other studies 
found no differences (Moloney et al., 2010; Liu et al., 2011; 
Ho et al., 2012; Talbot et al., 2012). The most convincing, 
consistent change in IS is a lower level of IR substrate 1 
(IRS1) and higher p(Ser)-IRS1, a marker of insulin resistance, 
in AD brains (Steen et al., 2005; Moloney et al., 2010; Bom-
fim et al., 2012; Talbot et al., 2012; Yarchoan et al., 2014). 
Higher p-JNK, which can lead to p(Ser)-IRS1, has also been 
found in AD brains (Bomfim et al., 2012; Talbot et al., 2012), 
suggesting some level of insulin resistance in AD. Questions 
still remain as to what are the physiological and pathological 
implications of increased markers such as p(Ser)-IRS1 and 
p-JNK and how that relates to AD pathology and brain function.
Table 1. Insulin-related changes in AD
Parameter AD ↑ ↓ Study Details
Blood insulin ↑ Bucht et al., 1983; Fujisawa et al., 
1991; Stolk et al., 1997; Craft 
et al., 1998; Ma et al., 2016
-Fasting or after glucose tolerance test -In women only (1 study) -Only in non-APOE4 and 
moderate/severe AD (1 study) -Meta-analysis of 11 studies: 5 report overall ↑, 1 ↑ in 
women, 1 ↑ with advanced stage (Ma et al., 2016)
CSF insulin ↑ Fujisawa et al., 1991 -Also found small increase with vascular dementia
↓ Craft et al., 1998; Gil-Bea et al., 
2010
-Only in non-APOE4 and moderate/severe AD -No relationship to APOE or AD severity 
No change Molina et al., 2002 -No relationship with AD severity or cognition
Brain insulin No change Frölich et al., 1998 -Comparing controls >65 y/o and AD patients
↓ Frölich et al., 1998; Rivera et al., 
2005; Steen et al., 2005
-Comparing controls <65 y/o and AD patients -mRNA: in hippocampus and hypothalamus 
-mRNA: progressive reduction with Braak stage
Brain IR (total) ↓ Frölich et al., 1998; Rivera et al., 
2005; Steen et al., 2005
-Comparing controls <65 y/o and AD patients -mRNA and protein -mRNA: progressive 
reduction with Braak stage
↑ Frölich et al., 1998 -Comparing controls >65 y/o and AD patients
No change Moloney et al., 2010; Liu et al., 
2011; Ho et al., 2012; Talbot et 
al., 2012
-Potential changes in cellular distribution -Also no change in p-IR -Only reduced in patients 
with T2D and AD
Brain p-IR and activity ↓ Frölich et al., 1998; Rivera et al., 
2005; Steen et al., 2005
-In hippocampus -Reduced insulin binding -TK activity reduced compared to all controls
Brain IRS1 (total) ↓ Steen et al., 2005; Moloney et 
al., 2010
-mRNA in 3 regions -Also reductions in IRS2
No change Liu et al., 2011; Talbot et al., 2012 -Also no change in IRS2 -Only reduced in patients with T2D and AD
Brain p(Ser)-IRS1 ↑ Moloney et al., 2010 Talbot et 
al., 2012 Bomfim et al., 2012 
Yarchoan et al., 2014
-Regardless of APOE status and reduced ex vivo insulin stimulation -Highest in AD, but also 
elevated in some tauopathies
Brain AKT (total) ↓ Griffin et al., 2005; Liu et al., 2011 -Reduced in AD and in patients with T2D and AD
No change Steen et al., 2005; Talbot et al., 
2012
Brain p-AKT  ↑ Pei et al., 2003; Griffin et al., 
2005; Talbot et al., 2012; 
Yarchoan et al., 2014
-Associated with tangles
↓ Steen et al., 2005 -In hippocampus
No change Liu et al., 2011 -Only reduced in patients with T2D and AD
Brain GSK3 (total) ↓ Ho et al., 2012 -With advanced AD
No change Steen et al., 2005; Liu et al., 2011; 
Talbot et al., 2012
-Only reduced in patients with T2D or T2D and AD
Brain p(Ser)-GSK3 ↓ Steen et al., 2005 Griffin et al., 
2005
-In hippocampus
No change Liu et al., 2011 -Only reduced in patients with T2D or T2D and AD
Brain p-GSK3 ↑ Pei et al., 2003 -Associated with tangles
Brain p-JNK ↑ Bomfim et al., 2012; Talbot et 
al., 2012
Other IR signaling 
molecules
 ↓ Griffin et al., 2005; Liu et al., 2011; 
Talbot et al., 2012
-PDK1, p-PDK1 and p-PI3K -PIP3, PKC, p-mTOR, p-ERK2 -PTEN
Reported alterations in ins and brain IS in AD are categorized by the specific component measured, whether there have been reports of an increase, decrease (up and down arrows), or no 
change in individuals with AD, the studies that report this specific alteration, and important details. For blood and CSF insulin, AD diagnosis was based on clinical criteria. For postmortem 
analysis of brain insulin and IS components, AD was confirmed by clinical diagnosis and histological analyses. All reported changes were at the protein level unless mRNA is specified in the 
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Canonical IS posits that, upon activation of AKT by in-
sulin, glycogen synthase kinase 3 (GSK3) is serine phosphor-
ylated to reduce its activity. Active GSK3 phosphorylates tau 
among other substrates, suggesting that overly active GSK3 
may exacerbate tau phosphorylation and, ultimately, its aggre-
gation. In postmortem brain samples, there are reductions in 
p-AKT and p(Ser)-GSK3, suggesting increased GSK3 activity, 
which can lead to tau phosphorylation (Steen et al., 2005; 
Liu et al., 2011). In contrast, other groups report increases in 
p-AKT and p(Ser)-GSK3, even in the presence of elevated 
phosphorylated tau (p-tau) and tangles (Pei et al., 2003; Grif-
fin et al., 2005; Yarchoan et al., 2014), making this particular 
signaling component difficult to interpret. Reductions in the 
level or phosphorylation of other IS molecules are reported 
in AD brains (Liu et al., 2011; Talbot et al., 2012) and ex vivo 
activity assays have shown that tyrosine kinase activity, insu-
lin binding, and insulin stimulation are reduced in AD brains 
(Frölich et al., 1998; Rivera et al., 2005; Talbot et al., 2012).
Overall, there does appear to be some level of insulin re-
sistance in the AD brain. However, this is not specific to insu-
lin, as there are also reductions in both the levels and signaling 
of insulin-like growth factor (IGF) I and II (Steen et al., 2005; 
Moloney et al., 2010) and leptin signaling (Maioli et al., 2015). 
Although brain insulin and IGF resistance in the human AD 
brain are seen as detrimental, mouse studies have paradoxi-
cally shown that deleting IRs or IGF1 receptors in the brain 
is protective against amyloid plaque deposition (Freude et al., 
2009; Stöhr et al., 2013) and improves survival (Freude et 
al., 2009), demonstrating that there is much left to elucidate 
about the physiological consequences of reduced insulin or 
IGF1 signaling in the brain.
Blood and cerebrospinal fluid (CSF) insulin. Studies reported 
alterations in blood insulin in AD as early as 1983 (Table 1). 
Fasted blood insulin or insulin in response to a glucose chal-
lenge are higher in AD patients (Bucht et al., 1983; Fujisawa 
et al., 1991; Stolk et al., 1997; Craft et al., 1998; Ma et al., 
2016). The transport of insulin from blood to brain and CSF 
is a receptor-mediated process. This transport is saturable 
within physiological levels and is affected by numerous vari-
ables (Banks, 2004). The CSF/serum insulin ratio is subtly de-
creased with age (Sartorius et al., 2015). Craft and colleagues 
also found the CSF/serum insulin ratio to be lower in AD, 
where higher blood and lower CSF insulin was more prom-
inent with disease progression. Interestingly, they only found 
this change in AD patients without an APOE4 allele (Craft et 
al., 1998). Other groups who measured CSF insulin reported 
reductions but no difference with APOE4 (Gil-Bea et al., 
Figure 2. Connections between T2D and AD: cause or consequence? Big picture questions that need to be addressed to determine if insulin-related 
changes represent a cause or consequence of AD. In regards to the evidence that T2D increases the risk of AD, answering the questions in the top arrow 
will determine how and why T2D is a risk factor and the potentially causal role of insulin/IS. In regards to the idea that AD progression may lead to a dia-
betic phenotype, answering the questions in the bottom arrow will determine if and how AD pathology may affect insulin homeostasis and the potential 
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2010), no difference (Molina et al., 2002), or increases with 
higher CSF/plasma ratios (Fujisawa et al., 1991), making in-
terpretations of this data difficult. While reports of CSF insulin 
are variable, current data suggests that AD patients are likely to 
experience higher blood insulin. When trying to determine 
if this hyperinsulinemia could be a cause or consequence of 
disease, it is important to consider when hyperinsulinemia 
occurs in relation to the development of AD. Table 1 demon-
strates that blood insulin is higher in AD patients, and it may 
increase with disease progression (Craft et al., 1998), but other 
studies suggest that higher blood insulin, before diagnosis, 
may be present and influencing disease progression.
Changes in ins and IS: cause of AD?
A longitudinal study found that fasting hyperinsulinemia, 
even without T2D, doubled the risk of developing AD 
(Luchsinger et al., 2004). A cross-sectional study found that 
in AD patients without an APOE4 allele, hyperinsulinemia 
was also associated with an increased risk of AD (Kuusisto 
et al., 1997) and higher insulin was associated with amyloid 
deposition, visualized by amyloid imaging on positron emis-
sion tomography (PET) scans, before symptom onset (Wil-
lette et al., 2015). Taken together, these studies suggest that 
high insulin could play a causative role in AD, although the 
AD population can be heterogeneous and it is possible that 
causal mechanisms differ across subgroups of patients. Since 
Aβ and tau deposition begin to occur ∼15 yr before symp-
tom onset, these studies are difficult to interpret (Fig. 3). For 
example, high blood insulin before the onset of AD pathol-
ogy could increase the risk of Aβ/tau deposition because 
ins/IS is a primary instigator of disease. In contrast, amyloid 
accumulation which begins ∼15 yr before cognitive decline 
could lead to brain insulin resistance, with hyperinsulinemia 
acting as a secondary indicator of underlying pathology in 
AD, and contribute to cognitive decline. To properly clarify 
whether insulin is a cause or consequence of disease, blood 
and CSF insulin should be tracked longitudinally, beginning 
before the onset of AD pathology, during AD pathology 
accumulation while individuals are still normal (preclinical 
AD), and then during the clinical stage of AD. To date, no 
such study has been reported. Recent studies have started to 
analyze the relationship between insulin resistance and AD 
biomarkers during the asymptomatic, preclinical stage in at-
risk populations. In asymptomatic middle-age adults, insulin 
resistance was associated with higher CSF tau, p-tau (Starks 
et al., 2015) and Aβ42 (Hoscheidt et al., 2016). CSF insulin 
was not measured, but baseline levels of blood glucose, insu-
lin, and insulin resistance were no different between APOE4 
carriers and noncarriers at this early stage of disease (Starks 
et al., 2015). Additional studies of this type, measuring CSF 
insulin in addition to traditional AD biomarkers, will help 
to determine the temporal relationship between insulin dys-
regulation and AD progression.
Ins, IS, and Aβ. There are many studies suggesting that hyper-
insulinemia may be directly influencing the risk of AD by 
modulating Aβ. In vitro studies demonstrate that high insulin 
can lead to higher extracellular Aβ by affecting clearance 
mechanisms and Aβ degrading enzymes. Both insulin and Aβ 
are degraded by insulin degrading enzyme (IDE), and in the 
Figure 3. Where and when do changes 
in ins and IS affect AD? Colored lines 
represent our current understanding of the 
pathological timeline in AD. It is currently 
unclear when and where changes in ins/IS 
occur in this timeline. If changes in ins/
IS happen early, (1) they could initiate or 
potentiate amyloid accumulation to casu-
ally influence AD. If ins/IS changes appear 
around the time of symptoms (4), this 
could be a consequence of years of patho-
logical changes and may be directly related 
to cognitive decline. If changes in ins/
IS occur in the presymptomatic period (2 
and 3), they could be interacting with Aβ, 
tau, or metabolism to contribute to disease 
progression. Conversely, presymptomatic 
changes could be a result of tau or Aβ 
accumulation or metabolic perturbation. 
Additionally, it is possible that changes in 
ins/IS could simply push the symptomatic 
period to the left (earlier) without directly 
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presence of high insulin, IDE will preferentially degrade insu-
lin over Aβ (Qiu et al., 1998). In vivo experiments corrobo-
rate in vitro findings where Aβ clearance is significantly 
reduced in rats in the presence of high insulin (Shiiki et al., 
2004). In addition to affecting Aβ clearance, in vitro work 
demonstrates that high insulin increases extracellular Aβ con-
centrations by increasing production through IS (Gasparini et 
al., 2001). Conversely, inhibition of PI3K leads to reduced Aβ 
production (Stöhr et al., 2013). Crossing neuronal IR knock-
out mice to an APP transgenic mouse abolishes IR signaling 
in the brain and leads to reduced Aβ levels and amyloid depo-
sition, indicating that endogenous IS elevates Aβ in vivo 
(Stöhr et al., 2013). A recent study in mice found that injec-
tion of supraphysiological levels of insulin increased brain IS 
and possibly Aβ (Sajan et al., 2016). In earlier work by Craft 
and colleagues, intravenous infusion of insulin in healthy 
older adults by hyperinsulinemic-euglycemic clamps im-
proved performance on a declarative memory task, but in-
creased CSF Aβ in ‘older’ participants (Watson et al., 2003). 
These clamps also increased plasma and CSF Aβ in another 
cohort, and increased inflammatory markers in the CSF 
(Fishel et al., 2005). Collectively, data suggests that elevated ins 
can modulate Aβ, suggesting T2D could exacerbate AD 
pathogenesis over time via this mechanism.
A crucial, remaining question is whether physiolog-
ical, peripheral hyperinsulinemia seen in AD or T2D raises 
brain insulin enough in vivo to actively compete with IDE, 
activate IS, or increase Aβ since insulin transport across the 
blood brain barrier (BBB) is saturable at normal physiologi-
cal levels (Banks, 2004). A recent paper found that in several 
mouse models of T2D and in T2D monkeys, hyperinsulin-
emia was associated with higher brain IS and higher Aβ levels 
at baseline. Murine Aβ was reportedly measured by Western 
blot in these experiments but the concentration is typically 
so low that this method may not be sufficient to detect small 
changes. Regardless, insulin injection did not further increase 
IS or Aβ, which could be due to transport or receptor satu-
ration (Sajan et al., 2016). Overall, it still appears that hyper-
insulinemia can positively regulate Aβ, though further studies 
are needed to clarify this.
While high blood insulin may indicate higher brain ins/
IS, it is also possible that lower brain ins/IS leads to higher 
blood insulin as an attempt to compensate for the reduction. 
A longitudinal study found that both the highest and lowest 
quartiles for fasting insulin were associated with the devel-
opment of dementia (Peila et al., 2004). One mouse model 
of AD was found to have reduced brain insulin and some 
changes in IS that preceded the deposition of Aβ (Chua et 
al., 2012). These results suggest that low brain ins/IS may also 
affect Aβ. Unfortunately, they did not measure blood or CSF 
insulin to know how these measures fluctuate overtime in 
relation to amyloid deposition and brain ins/IS.
GSK3 can increase Aβ levels in vitro and inhibition of 
GSK3 by lithium can reduce APP processing and Aβ levels 
(Phiel et al., 2003). As shown in Fig.  1, insulin also inhib-
its GSK3 through canonical signaling which would suggest 
that adequate ins/IS may contain Aβ levels. So far, this has 
not been validated experimentally. Lowering blood insulin by 
destroying insulin-producing cells in a mouse model of AD 
reduces brain ins/IS and results in elevated Aβ levels (Wang 
et al., 2010). While the authors conclude that insulin defi-
ciency raised Aβ, these mice also have extreme hyperglycemia 
which we and others have recently shown can independently 
increase extracellular Aβ (Macauley et al., 2015; Chao et al., 
2016). Moreover, decreasing insulin production would lead 
to decreased IDE levels, which could affect Aβ since IDE is 
an Aβ degrading enzyme.
While hyperinisulinemia can initially increase brain 
insulin and positively regulate Aβ acutely, chronic 
hyperinsulinemia can down-regulate transport leading to 
lower blood :brain insulin (Banks et al., 1997). This decrease in 
BBB transport may also increase Aβ, although there is no 
direct experimental evidence supporting this claim. Since it is 
unclear whether chronic hyperinsulinemia (described in 
Table 1) leads to increased brain insulin or to decreased insulin 
transport, additional experimental confirmation is required to 
identify a causal relationship with Aβ and AD.
Ins, IS, and tau phosphorylation. GSK3 activity is often con-
nected to the phosphorylation of tau. Neuronal IR knockout 
mice have higher p-tau, presumably due to more active GSK3 
(Schubert et al., 2004). Interestingly, these IR knockout mice 
do not have any memory deficits despite evidence that IS is 
connected to cognition and p-tau is linked with memory 
deficits in mice (Schindowski et al., 2006). Peripheral injec-
tion of supraphysiological insulin is capable of elevating IS in 
the mouse brain and increases p-tau even though GSK3 is 
serine phosphorylated by p-AKT to reduce activity and pre-
sumably p-tau (Freude et al., 2005). Hyperinsulinemia also 
increases p-tau in aged, wild-type mice (Becker et al., 2012). 
In vivo studies from mice agree with the complex findings 
from AD brains (Table  1) which found GSK3 to be both 
more active and less active while p-tau was high. Overall, 
these data suggest, again, that both high ins/IS (from hyperin-
sulinemia) and low IS (from insulin resistance) may put the 
brain at risk to exacerbate AD.
One study found that chronically raising blood insu-
lin in mice via a high fat diet had no effect on p-tau in the 
brain, but they also reported no change in brain IS (Becker 
et al., 2012). When injected peripherally with supraphysio-
logical insulin, p-tau was unchanged in mice with chronic 
hyperinsulinemia (Becker et al., 2012). Brain IS in response 
to the peripheral injection was not measured, but this likely 
demonstrates that insulin transport is reduced with chronic 
hyperinsulinemia. Additional evidence from a study in mice 
and monkeys demonstrates that chronic hyperinsulinemia re-
sulted in higher brain IS and higher p-tau (Sajan et al., 2016). 
They also found no further increase in IS with insulin injec-
tion, confirming that chronic hyperinsulinemia is most likely 
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the complexity between acute and chronic changes in blood 
insulin and insulin sensitivity in the brain that need to be 
considered when trying to understand how hyperinsulinemia 
and brain insulin resistance relate to each other and AD.
Changes in ins and IS: consequence of AD?
One AD population study found that up to 80% of AD pa-
tients had either T2D or insulin resistance, suggesting that 
AD may lead to a diabetic phenotype (Janson et al., 2004). 
Unfortunately, there are no longitudinal studies showing 
whether or not diabetic phenotypes occur after AD onset or 
precede AD diagnosis. Tissue analysis (Table 1) supports that 
brain insulin resistance worsens with advancing AD, but it 
is unclear how early in disease progression insulin resistance 
occurs (Fig. 3). If reduced brain IS is associated with cog-
nitive decline, one would expect changes to occur around 
the time that symptoms start to appear, which may be after 
blood insulin is already high. In T2D patients, insulin resis-
tance is also associated with brain hypometabolism (Baker et 
al., 2011). In AD, hypometabolism occurs before symptom 
onset and is likely related to synaptic dysfunction and neu-
ronal loss, and worsens with disease progression (Sperling et 
al., 2011). It is unclear how hyperinsulinemia, insulin resis-
tance, brain hypometabolism, and cognitive decline are tem-
porally related in AD (Fig. 3). A recent study used plasma 
exosomes from neural sources to measure p(Ser)-IRS1, a 
marker of insulin resistance, longitudinally in individuals 
with AD, T2D, or healthy controls (Kapogiannis et al., 2015). 
In these exosomes, p(Ser)-IRS1 was found to be higher in 
AD and T2D compared with controls, and was elevated up 
to 1–10 yr before AD diagnosis. However, there was no 
association of exosome p(Ser)-IRS1 with AD severity or 
insulin resistance, which is contrary to results from postmor-
tem brain tissue (Table 1). Determining which comes first, 
hyperinsulinemia or brain insulin resistance, would be the 
key to understanding which is a cause or consequence of 
AD and how they relate to AD pathogenesis.
In T2D, hyperinsulinemia is capable of leading to in-
sulin resistance through negative feedback at the IR (Fig. 1). 
Thus, it is possible that the hyperinsulinemia seen in AD pa-
tients may lead to brain insulin resistance or reduced insulin 
transport, which can modulate both Aβ and p-tau to con-
tribute to AD in a causal way. Although there is currently 
no longitudinal data demonstrating that hyperinsulinemia 
precedes the onset of AD pathology, there is mechanistic ev-
idence that it is possible for hyperinsulinemia to drive both 
insulin resistance and AD. Alternatively, insulin resistance in 
T2D can also be initiated by other processes, such as cellular 
stress and inflammation, which activate signaling molecules 
like p-JNK to increase p(Ser)-IRS1, causing hyperinsulin-
emia as a compensatory mechanism (Draznin, 2006). More-
over, oxidative stress and neuroinflammation are key features 
of the AD brain, which may promote brain insulin resistance, 
but most experiments have yet to explore these mecha-
nisms in the context of AD.
Aβ and brain insulin resistance. There is substantial evidence 
from in vitro experiments that Aβ may directly contribute to 
neuronal insulin resistance. Aβ can competitively inhibit the 
binding of insulin to the IR (Xie et al., 2002). Aβ oligomers 
(AβO) are thought to be the more toxic species of Aβ, and 
synthetic AβOs bind to and internalize IRs causing an in-
crease in neuronal p(Ser)-IRS1 and p-JNK, markers of insulin 
resistance (Zhao et al., 2008; Bomfim et al., 2012). In vivo 
experiments found higher p(Ser)-IRS1 and p-JNK in human 
AD brains (Table 1) and aged APP transgenic mice. They also 
found that intracerebroventricular injection of AβO’s into 
monkeys elevated p(Ser)-IRS1 and p-JNK, demonstrating 
that these AβO’s can cause resistance in vivo (Bomfim et al., 
2012). AβO’s increase p-tau, which may result from activation 
of GSK3 as a result of reductions in IS (Ma et al., 2009). Taken 
together, these data suggest that Aβ has the ability to induce 
insulin resistance in vitro and in vivo using several dif-
ferent model organisms.
Insulin treatment for brain insulin resistance. Craft et al. 
(1996, 1999, 2003, 2012) continue to demonstrate that insulin 
treatment, either by intravenous infusion or intranasal deliv-
ery, can modestly enhance performance on memory tasks in 
healthy adults and patients with AD or mild cognitive impair-
ment (MCI) at specific doses (Watson et al., 2003; Reger et 
al., 2008; Claxton et al., 2015). Gender and APOE4 modulate 
the beneficial effects of insulin (Craft et al., 2000, 2003; Reger 
et al., 2008; Claxton et al., 2013). In mice, intranasal adminis-
tration of insulin increases insulin in the cortex and hippo-
campus to some extent (Salameh et al., 2015), but whether or 
not it increases IS and confers protection against neuronal 
damage is still unknown. In vitro studies show that synthetic 
AβOs co-cultured with neurons can bind to synapses and re-
duce dendritic spines, an effect that is rescued when treated 
with high insulin and IS is activated (De Felice et al., 2009). 
Increasing hippocampal insulin and IS in rats also enhances 
memory. However, rats with T2D induced by a high fat diet 
did not show improvement with insulin treatment (McNay et 
al., 2010), suggesting that once brain insulin resistance has 
developed, insulin treatment may not be sufficient to over-
come resistance at a cellular level. In a mouse model of AD, 
high fat diet led to insulin resistance and exacerbated amyloid 
pathology and memory impairment. A single, supraphysio-
logical injection of insulin was found to improve IS in pe-
ripheral tissues and reduce soluble Aβ in the brain, but brain 
IS was not measured (Vandal et al., 2014). If insulin resistance 
is severe and causing brain insulin to be too low, increasing 
insulin under these conditions may help mitigate Aβ levels; 
however, this hypothesis was not directly tested. If brain IS is 
within normal range, insulin injection can increase IS and 
possibly Aβ levels (Sajan et al., 2016). Additionally, raising 
brain insulin by intranasal delivery appears to elevate brain 
insulin high enough that it may increase Aβ or p-tau, al-
though this has not been addressed in studies to date. Prelim-
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that this treatment may have some positive effects on memory 
and pathology (Chen et al., 2014; Zhang et al., 2016). Exten-
din-4, an antidiabetic medication thought to enhance IS by 
activating similar pathways, was able to prevent the develop-
ment of insulin resistance (p(Ser)-IRS1) in neuronal cultures 
and APP transgenic mice (Bomfim et al., 2012). Insulin sensi-
tizers that are used to treat peripheral insulin resistance, rather 
than insulin itself, may also be beneficial in AD. However, it is 
unclear if enhancing IS through insulin sensitizers can 
also modulate Aβ or p-tau.
The current hypothesis is that intranasal insulin is di-
rectly influencing cognition by acting on neuronal IRs to 
overcome resistance, but this has not been shown directly. 
Recent evidence has shown that intranasal insulin may be 
working through indirect pathways to influence cognition. 
For example, there have been reports of intranasal insulin in-
creasing regional cerebral blood flow and cognition in T2D 
patients (Novak et al., 2014). Insulin is thought to act through 
IRs on endothelial cells in the brain, but a recent study could 
not detect significant IR peptide in this cell type, despite IR 
mRNA being abundant (Zuchero et al., 2016). Determining 
the mechanism of intranasal insulin’s cognitive enhancement, 
and whether or not neuronal IS is necessary, will ultimately 
allow a more targeted therapeutic approach that may not have 
the potential side effect of raising Aβ or p-tau.
Concluding remarks
There is substantial experimental evidence that hyperin-
sulinemia and brain insulin resistance, seen in LOAD pa-
tients, is capable of increasing Aβ and p-tau to initiate or 
exacerbate the pathological cascade associated with AD. 
If patients experience high blood insulin before early AD 
alterations, hyperinsulinemia could causally contribute to 
both AD pathology and insulin resistance. However, there 
is not significant data to confirm this hypothesis in humans. 
Alternatively, initial Aβ accumulation can lead to neuronal 
insulin resistance and secondary hyperinsulinemia, which 
further exacerbates AD progression. Both longitudinal and 
biomarker studies need to be performed to properly under-
stand how high insulin in the blood, brain, or CSF, com-
bined with insulin resistance, relate to the progression of 
AD. Until that time, we should assume that the alterations 
in ins and IS represent both a cause and consequence of 
disease and need to be closely monitored as insulin therapy 
is investigated for AD.
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